drugset / Trial / NCT00581165

Study Evaluating Safety of Etanercept in Treatment of Patients With Moderate to Severe Psoriasiswith Etanercept

NCT00581165

Phase 4 Completed 500 enrolled Wyeth is now a wholly owned subsidiary of Pfizer
RandomizedSingle-groupOpen-labelTreatment

Summary

Evaluate (i) safety of etanercept in patients with moderate to severe psoriasis in Spain; (ii) the incidence of adverse events reported in these patients, and (iii) the role that age and concomitant therapy might play in the development of adverse reactions.

Timeline

Start
2006-02
Primary completion
2007-08
Completion
2007-08

Drugs

EvaluationDrugModalityDoseRoute
Subject Etanercept Protein / enzyme biologic 25 mg

Indications